Marcin J. Suskiewicz

Marcin J. Suskiewicz

A structural biologist and biochemist at the Centre de Biophysique Moléculaire, CNRS, Orléans, France. Interested in protein modifications and interactions.

Projects

ERC Starting Grant SUMOwriteNread (2023-2027)

The “SUMOwriteNread” project, dedicated to mechanisms of protein SUMOylation and its functional consequences, currently involves PhD students, Lucija Mance and Aanchal Mishra, a postdoc, El hadji Cisse, permanent engineers, Stéphane Goffinont and Franck Coste, and myself as a supervisor. We receive a lot of help from other group members and other scientists from the CBM and beyond.

What is protein SUMOylation? Small ubiquitin-like modifiers (SUMOs), discovered about 25 years ago, are members of the superfamily of ubiquitin-like proteins. We speak of protein SUMOylation when these proteins become covalently attached to intracellular target proteins, modifying their function, location or stability. SUMOylation plays an essential role in many biological functions and has strong links to disease, especially cancer. SUMOylation typically depends on enzymes called E3 ligases. Few SUMO E3 enzymes have been identified and characterised. The ERC-funded SUMOwriteNread project will fill this gap, identifying the structure and mechanism of action of some SUMO E3 ligases, developing approaches to identify and characterise new SUMO E3s, investigate mechanisms by which the specificity of SUMOylation is achieved, and finally to investigate the functional impact of SUMOylation in terms of triggering new protein:protein interactions.

The project is funded by a European Research Council (ERC) Starting Grant (ID 101078837) from the European Union, as part of the Horizon Europe programme. It is active from January 2023 until December 2027. Our budget amounts to € 1 493 515.

Other projects

We also have a small project funded by La Ligue contre le Cancer, dedicated to the cellular consequences of SUMOylation of PARP1, an important DNA damage sensor in human cells and a target of cancer therapeutics. This project is active from January 2023 until June 2024 and has a budget of € 25 000. I act as its supervisor, with a number of colleagues from the CBM involved as well.

In addition, we have several other active small projects related to protein modifications and protein interactions.